1. Introduction {#sec1}
===============

Obesity is a major contributor to chronic illness and premature death in many countries. Unfortunately, there are limited therapeutic options to help people lose weight. A promising avenue to counteract weight gain is through increasing the activity of thermogenic brown and beige adipocytes [@bib1]. Both of these cell types express high levels of Uncoupling Protein 1 (UCP1) in their mitochondria. When activated, UCP1 induces high rates of substrate oxidation with significant amounts of energy being expended in the form of heat [@bib1]. Thermogenesis in brown and beige adipocytes is activated in response to cold-exposure and protects animals against hypothermia [@bib2]. Additionally, UCP1 activity in brown and/or beige adipocytes regulates energy balance. Loss of UCP1 promotes weight gain in mice maintained at thermoneutrality and thus exempt from cold stress [@bib3]. Conversely, animals with increased brown and beige fat activity are lean and have a healthy metabolic profile [@bib4], [@bib5], [@bib6], [@bib7], [@bib8], [@bib9]. Importantly, brown/beige fat activity levels in people are also correlated with leanness [@bib10], [@bib11], [@bib12], [@bib13].

Brown adipocytes develop in dedicated depots of brown adipose tissue (BAT) and express relatively high levels of UCP1 under a variety of environmental conditions. By contrast, beige adipocytes, which develop in WAT, are highly inducible [@bib1]. In animals kept at normal vivarium conditions (∼22 °C), there are relatively few beige adipocytes. However, upon cold-exposure or chronic stimulation with β-adrenergic agonists such as CL 316, 243, there is a dramatic increase in beige fat cell recruitment and UCP1 levels. In mice, the cold-stimulated induction of beige adipocytes is particularly prominent in the inguinal WAT (ingWAT), a major subcutaneous fat depot. Importantly, recent studies have indicated that beige adipocyte activity affects systemic metabolism and contributes in a significant way to whole body insulin sensitivity [@bib14], [@bib15].

Brown adipocytes are distinct from the beige adipocytes found in ingWAT; they arise from separate lineages [@bib16], but many studies have suggested that the differentiation and development of both cell types are controlled by a shared transcriptional program. Work by our lab and others has shown that the transcription factor PRDM16 is required for "beiging" of ingWAT and for the maintenance of BAT [@bib6], [@bib15], [@bib17], [@bib18]. PGC-1*α*, a transcriptional co-activator also plays important roles in both brown and beige fat cells [@bib19], [@bib20]. We recently identified Early B-cell factor-2 (EBF2) as a factor required for the BAT development [@bib21]. Through an independent line of investigation, we also identified EBF2 as a selective marker of both brown and beige preadipose cells in embryonic and adult adipose depots [@bib22]. This raised the question of whether EBF2 plays a critical role in beige fat development and function.

In this study, we report that EBF2 controls beige adipocyte development in WAT. We show that genetic loss of *Ebf2* in mice blocks beige fat development and function without having any other obvious effects on WAT. EBF2 is required for the re-programming of primary ingWAT-derived preadipose cells into thermogenically competent beige/brown-like adipocytes *in vitro*. Finally, transgenic expression of *​Ebf2* in adipose tissue using the *Fabp4* promoter/enhancer powerfully stimulates beige fat development and protects animals against high fat-diet-induced weight/fat gain. RNAseq analysis demonstrates that EBF2 robustly induces a mitochondrial gene program similar to that of cold-induced beige fat. Overall, our results demonstrate that EBF2 plays a central role in regulating beige fat function and could potentially be manipulated to improve overall systemic metabolism in mice.

2. Materials and methods {#sec2}
========================

2.1. Animals {#sec2.1}
------------

All animal experiments were performed in accordance with an approved University of Pennsylvania Institutional Animal Care and Use Committee protocol. Mice were fed standard chow unless otherwise specified and kept on a 12 h light/dark cycle. *Ebf2* whole body knockout animals were obtained from R. Reed (Johns Hopkins, Baltimore, MD, USA) and have been described previously [@bib23]. *Fabp4-Ebf2* transgenic mice were generated by cloning full-length *Ebf2* cDNA downstream of the 5.4 kb *Fabp4* promoter/enhancer. A bovine growth hormone polyadenylation site was inserted 3′ to the *Ebf2* cDNA. The construct was injected into FVB mouse oocytes by the University of Pennsylvania Transgenic and Chimeric Mouse Facility. For CL 316,243 treatment, *Ebf2* knockout mice and wild type (WT) littermate controls were raised at thermoneutrality (30 °C) and injected with 1 mg/kg CL 316,243 diluted in PBS every day for 6 days. Mice were sacrificed for analysis on day 7. For weight gain analysis, *Fabp4-Ebf2* mice were housed at thermoneutrality and fed a 45% high-fat diet (Research Diets).

2.2. Cell culture {#sec2.2}
-----------------

Primary adipogenic precursor cells were isolated from mouse ingWAT as described previously [@bib24]. For adipocyte differentiation assays, cells were grown to confluence and then treated with differentiation induction medium (DMEM/F12 with 10% FBS, 1 μM dexamethasone, 0.5 mM isobutylmethylxanthine, 125 nM indomethacin, 20 nM insulin, and 1 nM T3). Induction medium was removed after 48 h and cells were then grown in DMEM/F12 medium containing 10% FBS, 1 nM T3 and 20 nM insulin until they were harvested. To stimulate a thermogenic program, cells were incubated either with 10 μM isoproterenol for 3 h or with 1 μM rosiglitazone for the entire differentiation time course. For Oil Red O staining, cell cultures were washed with PBS, fixed with 4% paraformaldehyde for 15 min and stained with Oil Red O solution for 30 min. All primary cell experiments were done using three technical replicates.

2.3. Western blot analysis {#sec2.3}
--------------------------

Cells or tissues were lysed in RIPA buffer containing 0.5% NP-40, 0.1% sodium deoxycholate, 150 mM NaCl, 50 mM Tris-Cl, pH 7.5, protease inhibitor cocktail (Complete; Roche) and 1 mM phenylmethylsulfonyl fluoride (PMSF). Protein concentrations were quantified using detergent-compatible (DC) protein assay kit (Bio-Rad). Lysates or nuclear fractions were run on Bis-Tris NuPAGE gels (Invitrogen), transferred to PVDF membrane (Millipore), and probed with primary antibody. Antibodies used were sheep anti-Ebf2 (R&D systems, AF7006), mouse anti-Ucp1 (R&D systems, MAB6158), rabbit anti-VDAC (Cell Signaling, 4866), mouse anti-actin (clone C4, Millipore, MAB1501) and mouse anti-tubulin (Sigma, T6199).

2.4. RT-qPCR analysis {#sec2.4}
---------------------

Total RNA was isolated from cultured cells or whole tissue using TRIzol extraction (Invitrogen). RNA was then purified using PureLink RNA columns (Life Technologies). RNA was reverse transcribed to generate cDNA using a High-Capacity cDNA Synthesis kit (Applied Biosystems). Real-time PCR was used to quantify transcript levels using SYBR Green master mix (Applied Biosystems) on a 7900 Fast HT real time PCR machine (Applied Biosystems). For all real-time PCR, *Tata-binding protein* (*Tbp*) was used as an internal normalization control. P-values were determined in Excel using a two-tailed T-test. Primer sequences are in [Table S1](#appsec1){ref-type="sec"}.

2.5. Histology {#sec2.5}
--------------

For immunohistochemistry, whole inguinal fat pads were fixed in 4% PFA overnight, dehydrated, and embedded in paraffin for sectioning. Sections were stained with hematoxylin and eosin using standard methods. For whole mount immunofluorescence staining of fat pads, mice were transcardially perfused with 2% paraformaldehyde in PBS. Inguinal fat pads were removed and 6 mm punch biopsies were taken from the fat pad region immediately adjacent to the lymph node. Tissues were incubated in 4% paraformaldehyde overnight, washed with PBS and blocked in PBS with 5% Normal Donkey Serum, 0.5% Triton X at 4 °C overnight. Tissues were incubated in primary antibody diluted in blocking solution overnight and secondary antibody diluted in block for 2 h at room temperature. Tissues were mounted on concavity slides in Prolong Gold antifade mounting medium. Slides were imaged on a Leica TCS Sp8 confocal microscope. Primary antibodies used were rabbit anti-UCP1 (1:1000, AZ) and sheep anti-EBF2 (1:200, R&D Systems). Secondary Alexa fluor-conjugated antibodies were from Life Technologies.

2.6. Tissue O~2~ consumption {#sec2.6}
----------------------------

A 6 mm punch biopsy was taken from each ingWAT sample directly below the lymph node. For BAT, one lobe was used. Tissues were weighed and minced in a respiration buffer (2% BSA, 1.1 mM sodium pyruvate, and 25 mM glucose in PBS). Oxygen consumption was measured for each sample in an MT200A Respirometer Cell (Strathkelvin) until oxygen consumption rate was stable (for approximately 5 min). Oxygen consumption rates were normalized to tissue weight. Two measurements were taken from each mouse.

2.7. RNAseq {#sec2.7}
-----------

An RNAseq library was prepared using isolated RNA from whole ingWAT pads with lymph nodes removed using the Illumina TrueSeq Library preparation kit. High-throughput sequencing was performed using a HiSeq 2000. All the high throughput sequencing was performed by the Functional Genomics Core at the University of Pennsylvania using HiSeq 2000 or 2500. RNA-seq reads were aligned to the UCSC mm9 using RUM [@bib25]. Differential gene expression analysis was performed using edgeR [@bib26], where differentially regulated genes with FDR \< 0.05 were selected for downstream analysis. Hierarchical clustering was performed based on log2-scaled gene expression value using 1− (correlation coefficient) as a distance measure and following Ward\'s criterion. Gene ontology analysis was done for up or down regulated genes separately using DAVID [@bib27], [@bib28] and significantly overrepresented terms from GOTERM_CC_FAT category were selected for presentation. Sequence data has been deposited into the Gene Expression Omnibus (GEO) database under the accession number [GSE74366](ncbi-geo:GSE74366){#intref0010}.

3. Results {#sec3}
==========

3.1. EBF2 is required for beige adipocyte development {#sec3.1}
-----------------------------------------------------

To determine if EBF2 regulates beige adipocyte development, we analyzed the beiging response of ingWAT in WT and *Ebf2* knockout (KO) animals. After outcrossing of *Ebf2* KO mice into the C57Black6 background, we found that, in contrast to previous studies [@bib21], [@bib23], the KO mice survive into adulthood at approximately 40% of expected Mendelian ratios when they are bred at thermoneutrality. The KO mice used in our experiments had slightly though not significantly lower body weights ([Figure S1A](#appsec1){ref-type="sec"}). ingWAT pads from *Ebf2* KO mice were comparable in both appearance and mass to WT ([Figure S1B](#appsec1){ref-type="sec"}).

To stimulate the beiging of WAT, we treated WT and KO animals with CL 316,243 (CL), a β3-selective adrenergic agonist [@bib29]. We confirmed by immunofluorescent staining a complete loss of EBF2 protein in the KO ingWAT ([Figure 1](#fig1){ref-type="fig"}A). *Hematoxylin* and *eosin* (H&E) staining prior to CL-treatment showed that WT and *Ebf2* KO ingWAT had a similar appearance, consisting mostly of large adipocytes with unilocular lipid droplets ([Figure 1](#fig1){ref-type="fig"}B). Following CL treatment, WT ingWAT showed regions of dense, multilocular adipocytes that were absent in CL-treated *Ebf2* KO ingWAT and non-treated controls ([Figure 1](#fig1){ref-type="fig"}B). Moreover, CL-treatment dramatically increased UCP1 protein expression in WT ingWAT with minimal induction of UCP1 in *Ebf2* KO ingWAT ([Figure 1](#fig1){ref-type="fig"}C).

To better characterize the beiging response, we used RT-qPCR to measure the expression levels of key genes involved in adipose function in WT and KO mice before and after CL injection. CL-treatment of WT mice did not affect *Ebf2* mRNA levels ([Figure 1](#fig1){ref-type="fig"}D). The levels of general adipogenic genes such as *Pparγ, AdipoQ* and *Fabp4* were not significantly affected by CL treatment, and levels of these factors were similar between WT and *Ebf2* KO tissue ([Figure 1](#fig1){ref-type="fig"}E), suggesting that EBF2 does not play a major role in general adipose development and maintenance. However, the CL-mediated induction of brown fat-selective genes like *Ucp1*, *Cidea*, *Pgc1α* and *Pparα* was severely blunted or nonexistent in *Ebf2* KO animals ([Figure 1](#fig1){ref-type="fig"}F). For example, CL increased *Ucp1* mRNA levels ∼1,700-fold in WT ingWAT and only ∼20-fold in KO tissue. The CL-mediated induction of *Cidea*, *Pparα* and *Pgc1α* expression was completely dependent on *Ebf2* ([Figure 1](#fig1){ref-type="fig"}F). *Prdm16* mRNA levels were not affected by *Ebf2* deletion or CL-treatment ([Figure 1](#fig1){ref-type="fig"}F).

Because the beiging process is also characterized by increased mitochondrial biogenesis and function, we assessed the levels of the mitochondrial genes and mitochondrial function in WT and *Ebf2* KO ingWAT. We found that the CL-mediated induction of mitochondrial genes (e.g. *Cox7a1, Cox8b* and Cytochrome C (*Cycs*)) was severely blunted or completely blocked by *Ebf2*-deficiency ([Figure 1](#fig1){ref-type="fig"}G). Consistent with the reduced expression levels of mitochondrial genes in *Ebf2* KO tissue, we found that oxygen consumption from *Ebf2* KO ingWAT was ∼40 percent less than oxygen consumption in WT ingWAT in mice that were housed at room temperature ([Figure 1](#fig1){ref-type="fig"}H). Taken together, these data show that *Ebf2* is required for induction of the beige fat-selective program in ingWAT.

3.2. The requirement for EBF2 in beige fat programming is adipose cell-autonomous {#sec3.2}
---------------------------------------------------------------------------------

We next examined whether EBF2 was required for the differentiation of beige adipocytes in a cell culture model. Primary adipogenic precursor cells from ingWAT can be induced to activate the brown/beige fat program in response to chronic treatment with the thiazolidinedione, rosiglitazone (rosi) [@bib30], [@bib31]. Notably, rosi treatment increased EBF2 mRNA and protein levels by ∼2-fold during the adipogenic differentiation of ingWAT-derived precursor cells ([Figure 2](#fig2){ref-type="fig"}A--B). To determine the requirement for *Ebf2* in the beiging process, we isolated and cultured WT and *Ebf2* KO ingWAT preadipose cells and confirmed that the KO cells did not express *Ebf2* ([Figure 2](#fig2){ref-type="fig"}B) These cultures were induced to undergo adipocyte differentiation and treated with rosi to induce beiging. Under basal conditions (without rosi), *Ebf2* KO cells differentiated into adipocytes less efficiently than WT cells as revealed by Oil Red O staining of lipid accumulation ([Figure 2](#fig2){ref-type="fig"}C). Consistent with reduced adipocyte differentiation, *Ebf2* KO cultures expressed lower levels the pan-adipocyte genes *Pparγ* and *Fabp4* ([Figure 2](#fig2){ref-type="fig"}D). This morphological and molecular differentiation defect was rescued, almost completely, by rosi treatment ([Figure 2](#fig2){ref-type="fig"}C--D). As anticipated, rosi treatment dramatically increased the expression of brown fat-selective genes (*Ucp1, Cidea, Pgc1α, Pparα, and Prdm16*) in WT adipocytes ([Figure 2](#fig2){ref-type="fig"}E--F). However, there was a severely blunted induction of these genes by rosi in *Ebf2* KO cells ([Figure 2](#fig2){ref-type="fig"}E--F). For example, rosi induced *Ucp1* expression by \> 1500-fold in WT cells and by only 30-fold in KO cells ([Figure 2](#fig2){ref-type="fig"}E). The rosi-mediated increases in the expression levels of mitochondrial genes (*Cox5b*, *Cox7a1*, *Cox8b*) were also drastically diminished in KO relative to WT cells ([Figure 2](#fig2){ref-type="fig"}G). Western blot analysis showed that rosi treatment induced UCP1 protein expression in WT but not in *Ebf2* KO adipocyte cultures ([Figure 2](#fig2){ref-type="fig"}H).

Thermogenic genes such as *Ucp1* are also acutely increased in mature brown/beige adipocytes in response to β-adrenergic agonists. To test if this requires *Ebf2*, we treated differentiated WT and KO primary adipocytes with the synthetic pan β-adrenergic agonist Isoproterenol (iso) for 3 h. Iso-stimulation robustly increased the expression levels of *Ucp1* and *Pgc1α* in WT adipocytes but only led to small increases in *Ebf2* KO adipocytes ([Figure 2](#fig2){ref-type="fig"}I). Altogether, these results reveal a critical requirement for *Ebf2* in the rosi- or β-agonist-mediated browning response of cultured adipocytes and strongly suggest that EBF2 acts in an adipose cell-autonomous manner to direct beige adipocyte development.

3.3. Ectopic expression of EBF2 is sufficient to drive conversion of white adipocytes to brown-like adipocytes {#sec3.3}
--------------------------------------------------------------------------------------------------------------

To determine if EBF2 is able to drive beige fat differentiation, we used retrovirus to overexpress EBF2 in primary ingWAT preadipocytes isolated from adult mice and treated with rosi ([Figure 3](#fig3){ref-type="fig"}A). EBF2-expression resulted in a subtle increase in the levels of the general adipogenic marker *Pparγ* although levels of *Adipoq* and *Fabp4* were unchanged ([Figure 3](#fig3){ref-type="fig"}B), suggesting that EBF2 overexpression has very little impact on adipocyte differentiation. By contrast, EBF2 dramatically increased the levels of brown fat-selective and mitochondrial genes, including: *Ucp1*, *Cidea, Pgc1α, Pparα, Prdm16, Cox7a1, Cox8b and Cycs* as compared to control cells ([Figure 3](#fig3){ref-type="fig"}C--D). While rosi treatment normally induced a large increase in *Ucp1* mRNA expression in primary ingWAT, EBF2-overexpression increased UCP1 even further at both the RNA ([Figure 3](#fig3){ref-type="fig"}C) and the protein levels ([Figure 3](#fig3){ref-type="fig"}E). Finally, we measured the levels of brown and beige adipocyte-selective marker genes [@bib16], [@bib32] in control and EBF2-expressing adipocytes. We found that while expression of EBF2 induced some brown-specific marker genes (*Eva1*, *Pdk4*, *Oplah*), it did not significantly increase in beige-specific genes ([Figure S2](#appsec1){ref-type="sec"}). Further, EBF2-expression did not reduce classical markers of white fat including *Agt* and *Retn* in these cultures ([Figure S2](#appsec1){ref-type="sec"}). Overall, we conclude that EBF2 drives a brown fat-like differentiation program when expressed in inguinal white preadipose cells.

3.4. Increased EBF2 activity in adipose tissue drives beiging {#sec3.4}
-------------------------------------------------------------

To determine if increasing EBF2 expression in WAT promotes beige adipocyte biogenesis, we analyzed transgenic mice that ectopically express *Ebf2* under control of the *Fabp4* enhancer/promoter, which drives expression in an adipose-selective manner. We first studied *Fabp4*-*Ebf2* and WT littermate adult male mice at room temperature. RT-qPCR analysis showed that *Ebf2* mRNA was elevated by between 4 and 8 fold in BAT, ingWAT and epididymal WAT (epiWAT) ([Figure 4](#fig4){ref-type="fig"}A). Western blot analysis indicated that EBF2 protein was overexpressed in BAT and ingWAT but not in epiWAT ([Figure 4](#fig4){ref-type="fig"}B). We first focused on the characterization of EBF2 overexpression in ingWAT. H&E staining revealed that the ingWAT of *Fabp4-Ebf2* mice accumulated large numbers of multilocular adipocytes, while the ingWAT of WT littermates had mostly large adipocytes with unilocular lipid inclusions ([Figure 4](#fig4){ref-type="fig"}C). Immunofluorescence staining showed that ingWAT from *Fabp4-Ebf2* mice displayed much higher UCP1 protein expression than ingWAT from WT littermates ([Figure 4](#fig4){ref-type="fig"}D). RT-qPCR analyses showed that transgenic expression of EBF2 did not alter the expression levels of general adipose markers (*Ppary, AdipoQ* or *Fabp4*) in ingWAT, indicating that the increased EBF2 expression does not affect overall development or maintenance of adipocytes ([Figure 4](#fig4){ref-type="fig"}E). However, in ingWAT, EBF2-overexpression led to a marked increase in the expression of many brown fat-selective genes including a ∼40-fold increase in *Ucp1* and 3- to 15-fold elevated levels of *Cidea, Pgc1α, Ppara* and mitochondrial genes (*Cox7a, Cox8b*, *Cycs*) relative to their levels in WT ingWAT ([Figure 4](#fig4){ref-type="fig"}F--G). Analysis of BAT and epiWAT tissues overexpressing EBF2 showed no significant change in mRNA levels for either general adipose genes or levels of brown fat-selective genes ([Figure S3A--B](#appsec1){ref-type="sec"}). This indicates that overexpressing EBF2 in adipose tissue primarily affects the ingWAT depot, which is the depot that is most permissive to beiging.

We then further examined global transcriptional effect of EBF2-overexpression using RNA-sequencing (RNAseq) to compare the gene expression profiles of ingWAT from WT and *Fabp4*-*Ebf2* mice ([Figure 4H--I](#fig4){ref-type="fig"}). RNAseq analysis showed that EBF2 activated a brown fat gene program, matching what we observed by RT-qPCR ([Figure 4](#fig4){ref-type="fig"}F--G, [Figure S3C](#appsec1){ref-type="sec"}). For example, the levels of white fat-specific genes, including *Retn* and *Leptin* were decreased by EBF2-expression while levels of brown fat-specific and mitochondrial genes such as *Ucp1*, *Cidea*, *Cox7a1*, *Cox8b*, and *Pparα* were increased. Gene Ontology analysis showed a high enrichment of metabolism and mitochondrial genes among the genes upregulated in *Fabp4-Ebf2* tissue ([Figure 4](#fig4){ref-type="fig"}H). Many of the genes induced by EBF2-overexpression in ingWAT were also previously shown to be induced in WAT by environmental cold-exposure ([Figure 4](#fig4){ref-type="fig"}I) [@bib33].

All the above analyses were performed in animals that were housed at room temperature. Under these conditions, the expression of *Ucp1* and other thermogenic/mitochondrial genes in ingWAT are stimulated, to some degree, by sympathetic nerve activity. To determine if the EBF2-mediated induction of thermogenic programming in ingWAT depends on sympathetic nerve activity, we studied WT and *Fabp4*-*Ebf2* mice that were housed at thermoneutrality to exempt the animals from cold stress. As anticipated, *Ucp1* expression in the ingWAT of WT mice was much higher at room temperature (∼30-fold) as compared to thermoneutrality ([Figure 4](#fig4){ref-type="fig"}J). Interestingly, EBF2-expression led to a larger fold increase in *Ucp1* levels under thermoneutral conditions than under room temperature condition (∼80 fold vs. ∼40 fold). This result shows that EBF2 can induce thermogenic gene expression in the absence of thermal stress ([Figure 4](#fig4){ref-type="fig"}J).

3.5. EBF2-expression increases mitochondrial activity in ingWAT and counteracts high fat diet-induced weight gain {#sec3.5}
-----------------------------------------------------------------------------------------------------------------

To determine if elevated EBF2 levels increased mitochondrial activity in ingWAT, we measured the oxygen consumption of isolated ingWAT from WT and *Fabp4-Ebf2* mice housed at room temperature using a Clark electrode. We found that the transgenic tissue had a 2.5-fold higher rate of oxygen consumption than WT tissue ([Figure 4](#fig4){ref-type="fig"}K). Notably, oxygen consumption of BAT was not increased in the transgenic animals ([Figure S3D](#appsec1){ref-type="sec"}). These results further suggest that increased EBF2 expression selectively increases the mitochondrial activity of ingWAT.

We next examined if *Fabp4-Ebf2* animals were protected against high fat diet (HFD) -induced weight gain. We placed WT and *Fabp4-Ebf2* mice on a HFD at thermoneutrality (30 °C) beginning at 5-weeks of age. After 12-weeks, *Fabp4-Ebf2* mice showed significantly reduced weight gain compared to WT mice ([Figure 4](#fig4){ref-type="fig"}L). By 15-weeks on a HFD, WT mice showed a percent weight gain of 116% while *Fabp4-Ebf2* had a percent weight gain of only 71%. NMR studies of body composition showed that *Fabp4-Ebf2* mice had ∼50% reduced fat mass with only a slight reduction in lean mass as compared to WT controls, and ingWAT pads were visibly reduced in size ([Figure 4](#fig4){ref-type="fig"}M,N). These results demonstrate that overexpression of EBF2 in ingWAT can suppress HFD-induced weight gain.

4. Discussion {#sec4}
=============

The storage of excess energy in WAT is associated with many health problems including heart disease, diabetes and cancer. The thermogenic capacity of brown fat has attracted interest as a potential target for anti-obesity therapy [@bib1]. While many mammals, including human infants, have interscapular brown fat, adult humans also have additional depots that contain beige adipocytes [@bib16], [@bib32], [@bib34], [@bib35]. Our lack of understanding of the factors that control the induction of beige fat limits our ability to target beige adipocytes for anti-obesity therapy. In this study, we show that EBF2 is a critical regulator of beige fat development and that its overexpression in adipose tissues activates a thermogenic and anti-obesity program.

EBF2 is selectively expressed in brown and beige adipogenic precursor cells relative to muscle or white fat precursors [@bib22]. Moreover, EBF2 regulates the expression of many preadipose-selective genes at the precursor stage, suggesting that it has an important role in preadipocyte commitment. In mature adipocytes, EBF2 directly regulates the expression of *Ucp1* and other brown fat-specific genes [@bib21]. An interesting question is whether EBF2 drives the beiging process mainly through functions in adipogenic precursors and/or adipocytes. The *Fabp4* promoter is active in mature adipocytes and in a subset of adipogenic precursors [@bib36]. Therefore, beige induction in the WAT depots of *Fabp4-Ebf2* mice may depend on EBF2 activation before or during differentiation as well as in mature adipocytes. Future studies will determine if EBF2-activation in a fully mature adipocyte can stimulate thermogenic programming *in vivo*.

EBF2 cooperates with the master adipocyte regulator PPARγ at enhancers of brown fat-selective genes to activate transcription [@bib21]. Synthetic PPARγ activators, particularly in the TZD class, are among the most effective inducers of the beige fat differentiation program in mouse and human adipocytes [@bib30], [@bib31], [@bib37], [@bib38], [@bib39], [@bib40]. Interestingly, we found that rosi treatment and EBF2-expression synergized to drive beiging in cultured adipocytes. A recent study suggests that rosi drives the beige program through activation of SIRT1, a de-acetylase [@bib8]. Mechanistically, SIRT1 de-acetylates PPARγ, which can then recruit PRDM16 and activate brown fat genes. In light of our findings, it would be interesting to examine whether de-acetylated PPARγ has higher affinity for EBF2-bound enhancer regions in brown/beige-fat selective genes.

Elevated EBF2 activity stimulates beiging in ingWAT but does not increase the levels of UCP1 and other brown fat genes in the BAT. This suggests that increases in the thermogenic capacity of ingWAT and possibly other WAT depots are responsible for reducing weight gain in *Fabp4-Ebf2* animals. In our study, *Fabp4-Ebf2* mice gained less weight than WT animals while housed at thermoneutrality and fed a HFD. HFD-induced thermogenesis, which depends on UCP1-function, is known to make an important contribution to energy expenditure in mice that are housed at thermoneutrality [@bib3]. We assume that HFD activates UCP1 and thermogenesis in EBF2-induced beige fat, presumably via increases in sympathetic outflow to adipose. Future studies will determine if EBF2-activation in adipose produces additional systemic metabolic benefits beyond its effects on body weight.

The epididymal WAT of *Fabp4*-*Ebf2* mice had increased *Ebf2* mRNA but not protein expression. This is reminiscent of analogous results obtained using a similar *Fabp4* cassette to express *Prdm16* and *Zfp516* in adipose tissues [@bib6], [@bib7]. In our work on *Fabp4*-*Prdm16* mice [@bib6], we speculated that PRDM16 might be translated less efficiently or de-stabilized in the epididymal depot for interesting biological reasons. But, given that at least three cDNAs expressed from a related transgene construct display the same behavior, it is more likely that the 3′ UTR (e.g. 3′ UTR from *Bovine growth hormone*) may somehow prevent efficient protein translation in epididymal WAT. This means that the effect of overexpressing beiging factors like PRDM16, ZFP516 or EBF2 in epididymal WAT remains unknown but of substantial interest. It is also important to point out that while the *Fabp4* promoter/enhancer cassette is an extremely useful and convenient tool to drive transgene expression in adipose tissue, *Fabp4* expression is not restricted to adipose tissue [@bib41], [@bib42]. In line with this, we found very low but detectable levels of transgene expression in non-adipose tissues ([Figure S4](#appsec1){ref-type="sec"}). Thus, while the reduced weight gain in *Fabp4-Ebf2* mice is very likely due to the adipose-autonomous action of EBF2, we cannot rule out the possibility that ectopic expression of EBF2 in other tissues affects the metabolism of these mice.

In summary, we have established that EBF2 is a powerful regulator of brown and beige fat biogenesis and that activation of EBF2 in adipose tissue has anti-obesity effects. Although the role of EBF2 in human body weight regulation remains to be explored, genome-wide association studies have identified a SNP (rs10503776) in exon 11 of *EBF2* that is highly associated with an increase in mean BMI [@bib43], indicating that the role of EBF2 in energy balance might be conserved in humans. Increased brown/beige fat activity in humans correlates with decreased BMI [@bib12], so promising targets to increase the activity of these tissues in people could be of great therapeutic value.
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![*Ebf2* is required for *in vivo* beiging of ingWAT. **(A)** Confocal immunofluorescence imaging of whole-mount ingWAT tissue. EBF2 protein is present in wild type (WT) but not *Ebf2* KO ingWAT. **(B)** H&E staining of ingWAT from WT and *Ebf2* KO mice before (left panels) or after (right panels) injection with CL-316,243 to induce beiging. **(C)** Confocal immunofluorescence imaging of whole-mount ingWAT tissue. UCP1 protein is highly expressed in WT but not *Ebf2* KO IngWAT following CL 316,243 injection. **(D**--**G)** Relative mRNA levels from in WT or *Ebf2* knockout ingWAT before and after CL 316,243 injection as measured by RT-qPCR. Levels of **(D)***Ebf2*, **(E)** the general adipose genes *Pparϒ, AdipoQ* and *Fabp4*, **(F)** the brown selective genes *Ucp1, Cidea, Pgc1α, Pparα* and *Prdm16*, and **(G)** the mitochondrial genes *Cox7a1, Cox8b, Cycs*. (n = 3). **(H)** Relative oxygen consumption of ingWAT from WT and *Ebf2* KO mice. (n = 4). P-values are represented with asterisks (\*, p-value ≤ .05; \*\*, p-value ≤ .01; \*\*\*, p-value ≤ .001) and error bars represent SEM. Scale bars = 10 microns.](gr1){#fig1}

![*Ebf2* is required for beiging. **(A)** Relative EBF2 protein levels from WT primary ingWAT stromal vascular cells plus or minus rosi treatment as assayed by western blot. **(B)** Relative *Ebf2* mRNA levels from WT or *Ebf2* KO primary ingWAT stromal vascular cells before and after rosi treatment as measured by RT-qPCR. (**C)** Oil Red O staining of differentiated and rosi treated WT or *Ebf2* KO primary ingWAT stromal vascular cells. **(D**--**G)** Relative mRNA levels from WT or *Ebf2* KO primary ingWAT stromal vascular cells plus or minus rosi treatment as measured by RT-qPCR. Levels of (D) the general adipose genes *Pparϒ* and *Fabp4*, (E) the brown selective genes *Ucp1* and *Cidea,* (F) the brown selective genes *Pgc1α, Pparα* and *Prdm16*, and (G) the mitochondrial genes *Cox5b, Cox7a1, Cox8b*. **(H)** Western blot to measure protein levels of UCP1 in differentiated and rosi treated WT or *Ebf2* knockout primary ingWAT stromal vascular cells. NS = non-specific band loading control. **(I)** Relative *Ucp1* and *Pgc1α* mRNA levels from WT or *Ebf2* knockout primary ingWAT stromal vascular cells before and after Iso treatment as measured by RT-qPCR. P-values are represented with asterisks (\*, p-value ≤ .05; \*\*, p-value ≤ .01; \*\*\*, p-value ≤ .001) and error bars represent standard deviation.](gr2){#fig2}

![EBF2-expression drives a brown fat/thermogenic profile in primary adipocytes. **(A**--**C)** Relative mRNA levels from control or retroviral EBF2-expressing primary ingWAT stromal vascular cells with or without rosi treatment as measured by RT-qPCR. Levels of (A) *Ebf2,* (B) the general adipose genes *Pparϒ, AdipoQ* and *Fabp4*, and (C) the brown selective genes *Ucp1, Cidea, Pgc1α, Pparα* and *Prdm16*, and (D) the mitochondrial genes *Cox7a1, Cox8b, Cycs*. **(E)** Western blot to measure protein levels of EBF2 and UCP1 levels in control or retroviral EBF2-expressing primary ingWAT stromal vascular cells following rosi treatment. P-values are represented with asterisks (\*, p-value ≤ .05; \*\*, p-value ≤ .01; \*\*\*, p-value ≤ .001) and error bars represent standard deviation.](gr3){#fig3}

![Ectopic ingWAT expression of EBF2 induces beiging *in vivo*. **(A)** qPCR of relative *Ebf2* mRNA levels from WT (white bar) and *Fabp4-Ebf2* (black bar) mice in BAT, ingWAT and epiWAT (mice housed at room temperature). (n = 3). **(B)** Western blot to measure EBF2 protein levels in WT or *Fabp4-Ebf2* (TG) mice in ingWAT, BAT and epiWAT (mice housed at room temperature). **(C)** H&E staining of ingWAT from WT and *Fabp4-Ebf2* mice. **(D)** Confocal immunofluorescence imaging of UCP1 protein levels in ingWAT from WT or *Fabp4-Ebf2* mice. **(E**--**G)**) Relative mRNA levels from WT and *Fabp4-Ebf2* ingWAT as measured by RT-qPCR. Levels of (E) the general adipose genes *Pparϒ, AdipoQ* and *Fabp4*, (F) the brown selective genes *Cidea, Pgc1α, Pparα* and *Prdm16* and (G) mitochondrial genes *Cox7a1, Cox8b, Cycs*. **(H)** Heat map of the top up-regulated and down-regulated genes in *Fabp4-Ebf2* ingWAT compared to WT, with corresponding GO analysis. **(I)** Cross comparison between RNAseq data comparing WT and Fabp4-Ebf2 ingWAT gene expression and microarray comparing thermoneutral and cold exposed ingWAT. The majority of overlapping upregulated genes are related to mitochondrial function. **(J)** Relative UCP1 mRNA levels of WT (white bars) and *Fabp4-Ebf2* (black bars) ingWAT from mice housed at thermoneutrality (TN, 30 °C) or room temperature (RT) as measured by RT-qPCR. **(K)** Relative oxygen consumption of ingWAT from WT and TG *Fabp4-Ebf2* mice housed at room temperature, n = 4. **(L)** Body weight of wild type (square) and TG *Fabp4-Ebf2* (circle) for mice housed at thermoneutrality on HFD beginning at 5 weeks of age. (n = 5). **(M)** Fat mass and lean weight mass of WT or TG *Fabp4-Ebf2* (n = 5) mice after 25 weeks on HFD at TN. **(N)** Gross histology of ingWAT fat pads from WT or TG *Fabp4-Ebf2* mice after 25 weeks on HFD at TN. P-values are represented with asterisks (\*, p-value ≤ .05; \*\*, p-value ≤ .01; \*\*\*, p-value ≤ .001) and error bars denote SEM. Scale bars = 10 microns.](gr4){#fig4}
